Ionis Pharmaceuticals, Inc.
IONS
Rankning i aktier
#2558
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Aktiekurs
$45.20
Senast synkroniserad: 2026-10-20
Marknadsvärde
$7.51B
Förändring (1 dag)
1.85%
Förändring (1 år)
-36.91%
Land
US
Handel Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Antal utestående aktier för Ionis Pharmaceuticals, Inc. (IONS)
Antal utestående aktier per June 2026: 165.42M
Enligt de senaste finansiella rapporterna och aktiekursen för Ionis Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 165.42M. I slutet av December 2023 hade företaget 143.00M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Ionis Pharmaceuticals, Inc. (IONS) från 2000 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 165.42M | 10.64% |
| 2024 | 149.51M | 4.56% |
| 2023 | 143.00M | 0.81% |
| 2022 | 141.85M | 0.59% |
| 2021 | 141.02M | 1.01% |
| 2020 | 139.61M | -0.28% |
| 2019 | 140.00M | 5.80% |
| 2018 | 132.32M | 6.70% |
| 2017 | 124.02M | 2.66% |
| 2016 | 120.80M | 1.26% |
| 2015 | 119.29M | 1.36% |
| 2014 | 117.69M | 6.51% |
| 2013 | 110.50M | 9.87% |
| 2012 | 100.58M | 0.92% |
| 2011 | 99.66M | 0.52% |
| 2010 | 99.14M | 1.05% |
| 2009 | 98.11M | 3.75% |
| 2008 | 94.57M | 12.93% |
| 2007 | 83.74M | 12.69% |
| 2006 | 74.31M | 18.18% |
| 2005 | 62.88M | 11.01% |
| 2004 | 56.64M | 2.13% |
| 2003 | 55.46M | 1.80% |
| 2002 | 54.48M | 23.51% |
| 2001 | 44.11M | 19.14% |
| 2000 | 37.02M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 53.49% |
US
|
|
| 396.00M | 139.39% |
US
|
|
| 478.91M | 189.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.41% |
NL
|
